Advertisement

Topics

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

2018-05-21 18:19:10 | BioPortfolio

Published on BioPortfolio: 2018-05-21T18:19:10-0400

Clinical Trials [3555 Associated Clinical Trials listed on BioPortfolio]

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer

This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic non-small cell lung cancer. Blood samples will also be collected for research purposes.

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic advanced bladder cancer. Blood samples will also be collected for research purposes.

PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

This study will evaluate the safety of PD-1 knockout engineered T cells in treating advanced esophageal cancer. Blood samples will also be collected for research purposes.

PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic advanced renal cancer. Blood samples will also be collected for research purposes.

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

The study is to assess the safety and efficacy of the immunotherapies using anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells in the treatment of patients with advanced esopha...

PubMed Articles [26634 Associated PubMed Articles listed on BioPortfolio]

Knockout of NCOA5 impairs proliferation and migration of hepatocellular carcinoma cells by suppressing epithelial-to-mesenchymal transition.

Nuclear receptor coactivator 5 (NCOA5) plays important roles in the development of a variety of malignancies. However, the underlying mechanisms remain obscure. In this study, we successfully generate...

Evaluation of the host immune response to decellularized lung scaffolds derived from α-Gal knockout pigs in a non-human primate model.

Whole organ tissue engineering is a promising approach to address organ shortages in many applications, including lung transplantation for patients with chronic pulmonary disease. Engineered lungs may...

Increase of viral hemorrhagic septicemia virus growth by knockout of IRF9 gene in Epithelioma papulosum cyprini cells.

Viral hemorrhagic septicemia virus (VHSV) has been a notorious pathogen in freshwater and marine fish. Due to the lack of effective treatment measures against VHSV disease, the development of prophyla...

Reproductive, physiological, and molecular outcomes in female mice deficient in Dhh and Ihh.

Ovarian development requires coordinate communications between oocytes, granulosa cells, and theca cells. Two Hedgehog (Hh) pathway ligands, desert (Dhh) and indian hedgehog (Ihh), are produced by the...

CRISPR/Cas9-mediated knockout of HIF-1α gene in epithelioma papulosum cyprini (EPC) cells inhibited apoptosis and viral hemorrhagic septicemia virus (VHSV) growth.

Hypoxia-inducible factor-1 (HIF-1) is a heterodimer of HIF-1α and HIF-1β, and its key role in the regulation of cellular responses to hypoxia has been well-demonstrated. The participation of HIF-1α...

Medical and Biotech [MESH] Definitions

Strains of mice that contain genetic disruptions (knockout) of APOLIPOPROTEINS E genes. They are used as models for ATHEROSCLEROSIS research.

Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.

Cell surface receptors for INTERLEUKIN-16. Although initial studies have identified CD4 ANTIGENS as receptors for interleukin-16, the fact that cells from KNOCKOUT MICE which lack CD4 antigen are responsive to IL-16 indicate that are at least 2 distinct receptors subtypes.

A broadly expressed type D cyclin. Experiments using KNOCKOUT MICE suggest a role for cyclin D3 in LYMPHOCYTE development.

Strains of mice arising from a parental inbred stock that was subsequently used to produce substrains of knockout and other mutant mice with targeted mutations.

More From BioPortfolio on "Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial